Welcome to the InfoSci Platform
Alliances may Explain the Significant Growth of Biotechnology Companies in the Critical Period 1996-2001?

Alliances may Explain the Significant Growth of Biotechnology Companies in the Critical Period 1996-2001?

Tomas Gabriel Bas
Copyright: © 2011 |Pages: 17
ISBN13: 9781616928469|ISBN10: 1616928468|EISBN13: 9781616928483
DOI: 10.4018/978-1-61692-846-9.ch006
Cite Chapter Cite Chapter

MLA

Bas, Tomas Gabriel. "Alliances may Explain the Significant Growth of Biotechnology Companies in the Critical Period 1996-2001?." Regional Innovation Systems and Sustainable Development: Emerging Technologies, edited by Patricia Ordóñez de Pablos, et al., IGI Global, 2011, pp. 57-73. https://doi.org/10.4018/978-1-61692-846-9.ch006

APA

Bas, T. G. (2011). Alliances may Explain the Significant Growth of Biotechnology Companies in the Critical Period 1996-2001?. In P. Ordóñez de Pablos, W. Lee, & J. Zhao (Eds.), Regional Innovation Systems and Sustainable Development: Emerging Technologies (pp. 57-73). IGI Global. https://doi.org/10.4018/978-1-61692-846-9.ch006

Chicago

Bas, Tomas Gabriel. "Alliances may Explain the Significant Growth of Biotechnology Companies in the Critical Period 1996-2001?." In Regional Innovation Systems and Sustainable Development: Emerging Technologies, edited by Patricia Ordóñez de Pablos, W.B. Lee, and Jingyuan Zhao, 57-73. Hershey, PA: IGI Global, 2011. https://doi.org/10.4018/978-1-61692-846-9.ch006

Export Reference

Mendeley
Favorite

Abstract

The biotechnology is a very complex sector and its growth depends on many variables like intellectual properties, venture capital, clusters, public policies, alliances, amongst others. In biotechnology, the complexity surrounding alliances can be observed. The market globalization, the exorbitant costs of R&D and the rapid changes in technology, are arguably in the midst of the principal reasons that push companies to establish alliances. Biotechnology companies use this instrument to develop external features in the search for resources and missing expertise. This chapter sets out to identify whether such alliances in biotechnology companies are an advantage in themselves, sufficient for the acquisition of new capabilities and whether they help the growth of these companies. For this approach, a private database of companies (900 companies including years 1996-2001) in the two most advanced countries in this sector: United States and United Kingdom will be used.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.